Orexigen (OREX) Reports Q3 Loss of $0.33, Beats by 3c
More News related to OREX
- Orexigen(R) Therapeutics to Speak at BIO CEO and Investor Conference
- Notable Analyst Rating Changes 02/02: AA, Q, AXP, FCX, ACHN Upgraded; JEC, VCLK, AVAV Downgraded
- Jefferies & Co Initiates Coverage on Orexigen Therapeutics (OREX) with a Buy
- Orexigen(R) Therapeutics to Present at JP Morgan Healthcare Conference
- Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
More News related to Earnings
- HNI Corporation (HNI) Tops Q1 EPS by 2c; Revs Light
- Team Health (TMH) Reports Mixed Q4 Results
- Baidu (BIDU) Blows the Lid Off Q4, Shares Jump
- Aspen Insurance (AHL) Posts Q4 adj.-EPS of $1.44, Tops Views
- Acadia Realty Trust (AKR) Misses Q4 FFO by 1c; Guides Below for FY10
Orexigen Therapeutics, Inc. (NASDAQ: OREX) reports Q3 loss of $0.33, 3 cents better than the analyst estimate of ($0.36).
Related Categories
EarningsStocks Mentioned
+0.07Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
